Castle Biosciences financials
$34.88−2.92%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $344.2M | $332.1M | $219.8M | $137.0M | $94.1M | $62.6M | $51.9M |
| Gross profit | $273.2M | $271.9M | $174.8M | $105.0M | $78.3M | $53.0M | $44.6M |
| Gross margin | 79.4% | 81.9% | 79.5% | 76.6% | 83.2% | 84.5% | 85.9% |
| Operating income | -$42.8M | $8.7M | -$68.0M | -$72.9M | -$40.1M | -$6.5M | $7.3M |
| Net income | -$24.2M | $18.2M | -$57.5M | -$67.1M | -$31.3M | -$10.3M | $3.0M |
| Net margin | −7.0% | 5.5% | −26.1% | −49.0% | −33.3% | −16.4% | 5.8% |
| Diluted EPS | $-0.83 | $0.62 | $-2.14 | $-2.58 | $-1.24 | $-0.54 | $-0.21 |
| EBITDA | -$2.0M | $24.7M | -$55.6M | -$80.6M | -$36.7M | -$6.1M | $7.7M |
| Operating cash flow | $64.3M | $64.9M | -$5.6M | -$41.7M | -$19.0M | $9.9M | $7.0M |
| Free cash flow | $28.3M | $36.5M | -$19.2M | -$47.3M | -$85.7M | $5.1M | $6.1M |
| Diluted shares | 29.0M | 29.3M | 26.8M | 26.1M | 25.1M | 18.9M | 8.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $116.7M | $119.7M | $98.8M | $122.9M | $329.6M | $409.9M |
| Short-term investments | $182.8M | $173.4M | $144.3M | $135.7M | $0.00 | — |
| Total debt | $10.4M | $10.3M | $25.0K | $0.00 | $0.00 | $0.00 |
| Total assets | $578.6M | $531.2M | $453.3M | $447.3M | $462.6M | $439.3M |
| Total liabilities | $107.7M | $75.4M | $62.1M | $48.2M | $50.8M | $23.6M |
| Shareholders' equity | $470.9M | $455.8M | $391.3M | $399.1M | $411.7M | $415.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology